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Measurement of response to treatment in colorectal liver metastases
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Department ofSurgury, Charing Cross and Westminster Medical School, Chelsea and Westminster Hospital, 369 Fulham Road,
London SWIO 9NH, UK.
Summary Assessment of tumour response to chemotherapy is important when assessing efficacy of treatment
and comparing differing therapeutic regimens. Percentage hepatic replacement (PHR) is commonly used to
assess response to treatment of colorectal hepatic metastases. PHR is dependent not only on tumour volume,
but also on hepatic parenchymal volume. The effect of tumour growth on hepatic parencymal volume is
unclear but is of importance owing to its effect on PHR. We assessed tumour and hepatic parenchymal
weights in an animal tumour model using dissection, and tumour and hepatic parenchymal volumes in patients
with colorectal hepatic metastases using CT scanning, in order to establish how hepatic parenchyma varied
with change in metastasis size. There was no significant correlation between tumour and liver parenchyma in
either the animal model (r = -0.03, P>0.05) or the patient study (r = 0.3, P<0.05). This suggests that
hepatic parenchymal volume was preserved in the presence of increasing tumour volume. In a further study of
computerised tomographic (CT) scans before and after treatment in patients whose tumours either responded
to chemotherapy or continued to grow, change in PHR (median proportion of PHR change = 0.40)
significantly (P = 0.04) underestimated the change in tumour volume (median proportion of tumour volume
change = 0.56), particularly at higher (>400 ml) volumes. There was good correlation between change in
tumour volume and WHO criteria in assigning patients to tumour growth, stable disease or tumour response
categories. This study suggests that, in clinical trials comparing colorectal liver metastasis treatments, metas-
tasis volume and not PHR should be used to assess extent of disease and the effect of treatment.
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More patients with colorectal liver metastases are being
treated with chemotherapy following studies which suggest
that chemotherapy prolongs survival (Erlichman et al., 1988;
Rougier et al., 1992; Allen-Mersh et al., 1994). As only
40-60% of colorectal liver metastasis patients respond to
chemotherapy (Dworkin et al., 1991), and the duration of
response is limited, it is necessary to monitor the effect of
treatment on the tumour - both after routine treatment and
in trials comparing treatments. Conventional chemotherapy
response criteria involve assessment of tumour shrinkage
(Allen-Mersh et al., 1987), a tumour partial response being
defined as a 50% reduction in tumour size in two dimen-
sions, measured either clinically or radiologically (Miller et
al., 1981). Although tumour response can be estimated, these
methods do not provide an estimate of extent of disease,
which is required in clinical trials in which treatment groups
must be balanced for extent of disease.
At present, the most accurate and reproducible method of
assessing colorectal liver metastasis size is by CT scanning
(Ward et al., 1988; Hunt et al., 1989). Measurement of area
of metastases and liver on each CT scan slice can be trans-
lated into volume by the principle of Delesse (1847). Res-
ponse can then be assessed by comparing percentage hepatic
replacement (PHR) before and after treatment (Breiman et
al., 1982). PHR is the quotient of the metastasis volume
divided by the total liver parenchymal and metastasis volume
expressed as a percentage and provides an indication of
extent of disease. As PHR is a ratio, it has the advantage of
removing scale change errors arising from variation in CT
scan protocols or equipment. However, PHR also depends
on liver parenchymal volume, and the relationship between
this and change in metastasis volume is not clear.
The aims of this study were to assess how liver paren-
chymal volume changes with metastasis growth or shrinkage,
and thereby to determine how closely PHR reflects change in
metastasis volume. In addition, we compared the accuracy of
conventional WHO criteria (Miller et al., 1981) in estimation
of tumour response with that of measurement of change in
tumour volume.
There were three parts to this study. First, we correlated
tumour and liver parenchymal weight change in a rat hepatic
metastasis model to determine how liver parenchymal weight
changed with tumour growth. Second, we estimated tumour
and liver parenchymal volume in patients with colorectal
hepatic metastases and assessed the extent to which PHR
change reflected tumour volume change. We then compared
PHR and tumour volume change in patients with either
tumour growth or treatment-induced tumour shrinkage to
determine whether differences predicted by the earlier study
occurred. We also assessed the correlation between estimates
of tumour growth or shrinkage provided by measurement of
tumour volume with estimates of tumour response obtained
using WHO criteria (Miller et al., 1981).
Materials and methods
Animal study
Seventy-one Chester Beatty Hooded rats were studied. Ani-
mals were fed and watered ad libitum before any experiments.
Each rat underwent laparotomy and intraportal injection of
500-1000 Hooded Sarcoma-N (HSN) cells. This is a rapidly
growing liver metastasis tumour model which grows by inva-
sion of adjacent parenchyma (SA Eccles, personal commun-
ication). Between 21 and 28 days after tumour inoculation
the animals were anaesthetised using 2% halothane, killed by
a bolus injection of strong potassium chloride, and the liver
removed. All hepatic tumours were carefully dissected from
the liver parenchyma, and both tumour and liver tissue
weighed separately. Previous studies suggested that metas-
tases are sufficiently discrete to be accurately separated from
normal liver parenchyma in this model (Eccles et al.,
1993).
Single-scan patient study
Forty-three patients with colorectal liver metastases under-
went a single-contrast enhanced liver CT scan consisting of
10-mm-thick contiguous axial slices.
The area of both the liver and of the metastasis was
separately determined in each CT scan slice using a Rei-
chert-Jung MOP image analyser. This figure was then con-
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verted to square millimetres using the scale given with each
CT scan. Volume for each slice was obtained by multiplying
this area by the slice thickness. The total volumes (liver and
metastasis) were derived by summing contiguous slices using
a previously described method (Breiman et al., 1982). Liver
parenchymal volume was also similarly assessed in 13 control
patients with normal livers undergoing abdominal CT for
unrelated conditions.
The correlation between variables was obtained using Pear-
son's correlation coefficient and differences between variables
were assessed using Student's t-test.
Sequential scan patient study
Twenty patients who had either uncontrolled metastasis
growth (n = 10) or treatment-induced metastasis shrinkage
(n = 10) were scanned on two separate occasions with a 4-6
month interval between scans. Measurements were made as
outlined above, and the extent of disease compared between
scans from the same patient using the paired-rank test. For
assessment of change in size by WHO criteria (Miller et al.,
1981), the product of the largest diameter ofa metastasis and
the largest perpendicular to that diameter was obtained for
every metastasis above 5 cm diameter. These were saved from
all scan slices, and the total before and after treatment
compared to determine whether there had been progressive
disease (>25% increase), stable disease (<25% increase to
<50% decrease), a partial response (> 50% decrease) or a
complete response (disappearance of visible tumour).
Results
Animal study
The median weight of animals studied was 320 g (range
290-360 g). There was no significant correlation between
liver parenchymal weight and metastasis weight (r=-0.03,
P>0.05) (Figure 1).
Single-scan patient study
There was no significant relationship (r = 0.3, P> 0.05)
between metastasis volume and hepatic parenchymal volume
(Figure 2).
There was no significant difference (P = 0.09, two-tailed
group t-test) in hepatic parenchymal volume between normal
liver controls (n = 13, mean volume 1574ml, s.d. 321 ml) and
hepatic metastasis patients (n = 43, mean volume 1308 ml,
s.d. 473 ml).
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Figure 1 There was no significant correlation (r = -0.03,
P>0.05) between liver parenchymal and tumour weight in an
animal model ofliver metastases, suggesting no liver parenchymal
loss with metastasis growth.
Sequential scanpatient study
The PHR and metastasis volume changes for tumours in
each metastasis growth or shrinkage patient are shown in
Figure 3. The overall proportion of PHR change (greater
PHR minus lesser PHR/greater PHR) (median 0.40, inter-
quartile range 0.25-0.68) was significantly (P = 0.04, paired
sign rank test) less than the proportion of metastasis volume
change (greater volume minus lesser volume/greater volume)
(median 0.56, interquartile range 0.40-0.75). This difference
was significantly greater (P = 0.02, paired sign-rank test) in
patients with a metastasis volume of >400ml compared
with <400ml.
There was no significant difference in liver parenchymal
volume before and after either tumour growth or tumour
shrinkage (Table I).
Figure 4 shows the correlation of change in metastasis size
between that measured using tumour volume and that using
WHO criteria. There was good agreement between the two
methods in assigning patients to either growth (>25% in-
crease), stable disease (<25% growth to <50% shrinkage)
or response () 50% shrinkage) categories.
Discussion
We found no evidence of an inverse relationship between size
of hepatic parenchyma and metastases in either the animal
study, which measured weight, or the patient single-scan
study, which measured volume. We were also unable to
demonstrate a significant difference in liver parenchymal
volume between subjects with a normal liver and patients
with liver metastases.
There was variation in liver parenchymal size in both
animal and patient studies. This could not be explained solely
by variation in body weight since the liver parenchymal
variation (x 2 in rats, x 4 in patients) was greater than body
weight variation (x 1.25 in rats, x 2 in patients). Some
additional variation in liver parenchymal volume may have
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Figure 2 There was no significant correlation (r = 0.3, P>0.05)
between liver parenchymal and tumour volume in patients with
liver metastases, suggesting no liver parenchymal loss with metas-
tasis growth.
Table I Liver parenchymal volume (median and interquartile range
(ml))
Before After P-value
treatment treatment (MWU)
Tumour growth 1486 1699
(1182-1738) (1287-2593) 0.27
Tumour shrinkage 1560 1508
(1432-2007) (1386-1608) 0.5
MWU, Mann-Whitney U-test.
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Figure 3 Volume and PHR change (plotted on a log scale) in 20
patients with either tumour growth or shrinkage. Line and bars
indicate median and interquartile ranges. Median tumour volume
change (0.56) was significantly greater (P = 0.04, paired sign-rank
test) than PHR change (0.40) in the same patient.
been due to errors in accurately assigning tissue to metastasis
or normal parenchyma. Previous comparison of human auto-
psy measurement of liver metastasis volume has suggested a
good correlation with CT scan assessment (Heymsfield et al.,
1979). Despite a much larger variation in metastasis size
(more than 20-fold) than the potential errors mentioned
above, we were unable to show any correlation between
metastasis size and liver parenchymal volume.
This suggests that liver parenchyma was not substantially
reduced by colorectal liver metastasis growth and indicates a
similar effect to that previously reported with growth of
10-fold smaller liver metastases (Purkiss and Williams, 1993)
than in our study. Thus, it appears that liver parenchymal
volume is preserved throughout the growth of colorectal liver
metastases.
It could be that liver parenchymal preservation occurs
because metastases grow non-invasively. However, local
invasion by liver metastases into the diaphragm suggests that
these metastases are readily capable of invasive growth. It is
more likely that liver parenchyma is invaded during metas-
tasis growth but that parenchymal regeneration occurs -
perhaps to sustain liver function.
A model of the relationship between PHR and tumour
volume during metastasis growth can be derived (Figure 5)
which assumes either metastasis replacement of liver paren-
chyma or parenchymal preservation. It can be seen that the
parenchymal preservation model predicts that PHR change
underestimates metastasis volume change, particularly at
higher (>400 ml) tumour volumes. A reduction in metastasis
volume from 1000 ml to 500 ml (a partial response by
volume) would involve a reduction in PHR from 40% to
25% (Figure 5) and would therefore not be considered a
partial response by PHR. The experimental data in our study
support this model.
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Figure 4 Change in tumour volume on vertical axis plotted
against change in tumour by WHO criteria on horizontal axis.
There was complete agreement between the two methods in
assigning patients to either progressive disease (>25% increase),
stable disease (<25% increase to >50% decrease) or partial
response () 50% shrinkage). (Increase plotted on log scale for
clarity.)
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Figure 5 Model predicting the relationship between tumour
volume and PHR assuming either liver preservation (lower line)
or replacement (based on liver parenchymal volume of 1500 ml).
It can be seen that the liver parenchymal preservation model
predicts that tumour volume change will be underestimated by
PHR change, particularly at higher tumour volumes.
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We found a good correlation between metastasis volume
and WHO criteria in assessment of response.
How should the effect of treatment of colorectal liver
metastases be assessed? Tumour volume and not PHR should
be assessed where extent of disease is required in studies
comparing liver metastasis treatments. WHO criteria pro-
vided an equivalent estimate of response, but as they do not
yield an estimate of extent of disease, cannot be used to
assign patients in order to ensure balanced treatment groups,
for example by minimisation (Taves, 1974).
CT scanning is currently the best widely available method
of assessing tumour volume, since it is less operator depen-
dent than ultrasound and allows assessment of size change in
more metastases than can usually be measured by ultra-
sound. However liver ultrasound is more widely available
and costs less. Where patients are being treated outside of a
trial, operator estimation ofmetastasis shrinkage using WHO
criteria (Miller et al., 1981) or fall in serum carcinoembryonic
antigen (CEA) indicates a treatment-derived survival benefit
(Allen-Mersh et al., 1987). Thus, reduction in metastasis size
on ultrasound or fall in serum CEA is suitable for assessing
routine treatment.
In conclusion, our study suggests that metastasis volume
should be reported in liver metastasis treatment studies.
Acknowledgements
SE and CF are Macmillan nurses supported by Cancer Relief/
Macmillan fund and MJD and DB are supported by the Britta
Dolan memorial cancer fund.
References
ALLEN-MERSH TG, KEMENY N, NIEDZWIECKI D, SHURGOT B
AND DALY JM. (1987). Significance of a fall in serum CEA
concentration in patients treated with cytotoxic chemotherapy for
disseminated colorectal cancer. Gut, 28, 1625-1629.
ALLEN-MERSH TG, EARLAM S, FORDY C, ABRAMS K AND
HOUGHTON J. (1994). Quality of life and survival in patients
with colorectal liver metastases treated with continuous hepatic
artery floxuridine. Lancet, 344, 1255-1260.
BREIMAN RS, BECK JW, KOROBKIN M, GLENNY R, AKWARI OE,
HEASTON DK, MOORE AV AND RAM PC. (1982). Volume deter-
minations using computed tomography. Am. J. Roentgenol., 138,
329-333.
DELESSE A. (1847). Procede mecanique pour determiner la composi-
tion des roches (abstract). CR Acad. Sci., 25, 544.
DWORKIN MJ AND ALLEN-MERSH TG. (1991). Regional infusion
chemotherapy for colorectal hepatic metastases - where is it
going? Cancer Treat Rev., 18, 213-224.
ECCLES SA, BOX G, COURT W, COLLINS MK AND DEAN CJ. (1993).
Monoclonal antibodies for the treatment of metastases. Evalua-
tion of strategies using a syngeneic rat model. Cell Biophys., 22,
165-187.
ERLICHMAN C, FINE S, WONG A AND ELHAKIM T. (1988). A
randomised trial of fluouracil and folinic acid in patients with
metastatic colorectal carcinoma. J. Clin. Oncol., 6, 469-475.
HEYMSFIELD SB, FULENWIDER T, NORDLINGER B, BARLOW R,
SONES P AND KUTNER M. (1979). Accurate measurement of
liver, kidney, and spleen volume and mass by computerized axial
tomography. Ann. Int. Med., 90, 185-187.
HUNT TM, FLOWERDEW ADS, TAYLOR I, ACKERY DM, BLAC-
QUIERE RM AND DEWBURY K. (1989). A comparison of
methods to measure the percentage hepatic replacement in col-
orectal liver metastases. Ann. R. Coll. Surg. Eng., 71, 11-13.
MILLER AB, HOOGSTRATEN B, STAQUET M AND WINKLER A.
(1981). Reporting results of cancer treatment. Cancer, 47,
207-214.
PURKISS SF AND WILLIAMS NS. (1993). Growth rate and percen-
tage hepatic replacement of colorectal liver metastases. Br. J.
Surg., 80, 1036-1038.
ROUGIER P, LAPLANCHE LA, HUGUIER M, HAY JM, OLLIVIER JM,
ESCAT J, SALMON R, JULIEN M, AUDY J-CR, GALLOT D, GOUZI
JL, PAILLER JL, ELISA D, LACAINE F, ROOS S, ROTMAN N,
LUBOINSKI M AND LASSER P. (1992). Hepatic arterial infusion
of Floxuridine in patients with liver metastases from colorectal
carcinoma: long-term results of a prospective randomised trial. J.
Clin. Oncol., 10, 1112-1118.
TAVES DR. (1974). Minimization: a new method of assigning
patients to treatment and control groups. Clin. Pharmacol. Ther.,
15, 443-453.
WARD BA, MILLER DL, FRANK JA, DWYER AJ, SIMMONS IT,
CHANG R, SHAWKER TH, CHOYKE P AND CHANG AE. (1988).
Prospective evaluation of hepatic imaging studies in the detection
of colorectal metastases: correlation with surgical findings.
Surgery, 105, 180-187.